MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from marketable
securities
$506,072K
Proceeds from long-term
liabilities and other
$29,731K
Proceeds from repayment
of loan from joint...
-$33,268K
Distribution from equity
accounted investees
$30,113K
Receipt of grant funding
$21,343K
Net cash provided by
(used in) investing...
$87,750K
Net cash provided by
financing activities
$14,082K
Effect of exchange rate
changes on cash and cash...
$1,097K
Canceled cashflow
$503,046K
Canceled cashflow
$15,649K
Increase (decrease) in
cash and cash...
-$28,366K
Canceled cashflow
$102,929K
Stock-based compensation
$55,792K
Depreciation of property and
equipment
$18,439K
Other assets
-$17,148K
Amortization of operating
lease right-of-use...
$6,650K
Fair value (gain)
loss on contingent...
-$4,529K
Amortization and impairment
of intangible...
$3,732K
Accounts payable and
accrued liabilities
$3,457K
Purchase of marketable
securities
$436,044K
Purchases of property and
equipment
$42,772K
Long-term investments and
other assets
$17,093K
Investment in and loans to
equity accounted...
$7,137K
Payment of liability for
in-licensing agreement and...
$15,649K
Net cash used in
operating activities
-$131,295K
Canceled cashflow
$109,747K
Net loss
-$146,412K
Research fees and grants
receivable
$55,623K
Income taxes (payable)
receivable
-$29,843K
Deferred grant income
$3,638K
Other
$3,331K
Deferred revenue
-$2,195K
Back
Back
Cash Flow
source: myfinsight.com
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)